This purpose of this research study is to collect feedback from participants about a web-based program for opioid misuse and opioid use disorder. Participants will be asked to review web-based content and take part in focus groups (group discussions) and individual interviews to provide feedback on the content. The study team is looking for pregnant women or women who have been pregnant in the past 2 years who misuse opioids or have opioid use disorder, as well as obstetric providers who treat pregnant women with opioid misuse and opioid use disorder to participate.
The purpose of this study is to determine if repetitive transcranial magnetic stimulation (rTMS) reduces opiate craving and pain in Veterans who are receiving treatment for opioid use disorder. The study will last approximately three months. There will be a screening visit to determine eligibility, followed by the treatment phase during which participants will receive six sessions of rTMS a day for three non-consecutive days. This period may take up to three weeks. There are follow up visits at one week, four weeks and three months after the treatment phase has ended.
During rTMS, focused magnetic waves are directed at a part of the brain that is important in pain, and craving, to increase its activity. If you participate, you will receive six sessions of either active rTMS, or placebo rTMS, each day for three days (18 total sessions). Each session lasts 15 minutes. People typically do not have side effects with rTMS, though they initially may find it mildly painful at the application site. About 1 out of every 20 people who get rTMS have mild headaches after sessions that are typically relieved with over-the-counter medicines. A few people who have had rTMS have had seizures, though the chance of this happening is very small.
Adolescents who regularly use cannabis will record their cannabis use in real-time via a mobile app for two weeks. Participants will be asked to report the method (i.e., joints, blunts, dabs), estimated quantity, and estimated potency of their recent cannabis use. In addition to monitoring cannabis use in real-time, participants will complete other assessments on the mobile app five times per day. Participants will attend three in-person office visits.
This study will examine the efficacy of intranasal oxytocin versus placebo in combination with Alcohol Behavioral Couples Therapy (ABCT) to reduce alcohol use disorder severity. We will also use observational coding and neuroimaging to examine behavioral and neural mechanisms underlying treatment outcomes.
The purpose of this study is to gather feedback to inform the development of a web-based tool that provides screening and education about alcohol use following interpersonal violence. People who have experienced sexual assault or domestic violence in the last year and drink alcohol, or are currently in treatment for alcohol use, will be asked to provide feedback about a web-based tool for alcohol use. 60-minute interviews will be conducted and will involve viewing the content of the web-based tool and providing feedback. Additionally, feedback given during interviews will be analyzed and then individuals who have used the web-based tool will complete a survey following the tool use if they report using substances.
The purpose of this study is to evaluate the efficacy of the medication N-acetylcysteine (NAC) to help young people with alcohol use disorder. NAC is an over-the-counter supplement and antioxidant that has been approved by the Food and Drug Administration (FDA) in adults and children for other uses, but has not been approved by the FDA for treatment of alcohol use disorder. All participants will receive brief alcohol counseling during the 8 weeks of medication treatment. Volunteers ages 13-20 are needed for this study.
This study will examine whether the investigational medication PF-0447845 is safe and effective in reducing cannabis use among people who frequently use cannabis. This is a 14-week, randomized, double-blind, placebo-controlled outpatient clinical trial that will be conducted at 4 research sites in the eastern U.S.
This study will evaluate the effect of counseling plus Approach Bias Modification on cannabis use and craving in people with cannabis use disorder. The study consists of a screening visit, four treatment visits and two follow-up visits. Participants will have 3 sessions of counseling, 4 sessions of Approach Bias Modification, and 3 cue reactivity sessions.
The first week after attempting to quite cigarette smoking is the hardest period to succeed. Research shows that individuals able to remain cigarette free for this first week are significantly more likely to quit the smoking habit. In this study, sponsored by the National Institutes of Health, we are evaluating a new tool to assist individuals with quitting cigarette smoking. Transcranial magnetic stimulation (TMS) is a non-invasive technique that uses magnetic pulses to temporarily stimulate specific brain areas (without the need for surgery, anesthetic, or other invasive procedures). This study will test whether 10 daily sessions of TMS over the forehead can help decrease smoking rates in treatment-seeking individuals.
The purpose of this study is to evaluate the potential mechanism of action and the safety of GET73, a new drug under development for the reduction of craving and drinking in alcohol dependent individuals. The study involves five to six visits over a three to four week period, including one to two assessment visits and two visits during which participants will be assigned to take, in a double-blinded fashion, both GET73 and a placebo (two visits during each condition). During three of these visits, participants will undergo a one-hour MRI scan. Compensation is available for qualified participants.